Toxicities Following CAR-T Therapy for Hematological Malignancies

Chimeric antigen receptor T-cell (CAR-T) therapy has improved outcomes in relapsed/refractory patients with hematological malignancies, including B-acute lymphoblastic leukemia (B-ALL), large B-cell lymphoma (LBCL), mantle cell lymphoma (MCL) and multiple myeloma (MM). The following CAR-T products are licensed in Europe and United States: tisagenlecleucel (tisa-cel) (Kymriah ®) for pediatric B-ALL [1] and LBCL [2]; axicabtagene ciloleucel (axi-cel) (Yescarta®) and lisocabtagene maraleucel (Breyanzi®) for LBCL [3,4]; brexucabtagene autoleucel (Tecartus®) for MCL [5]; idecabtagene vicleucel (Abecma®) for MM [6].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research